Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.
Corvidia Therapeutics is a clinical stage company focused on the research, development, and commercialization of transformative therapies for cardio-renal diseases. The Company is currently developing potential treatments for chronic kidney disease with atherosclerotic cardiovascular disease and inflammation, and high triglyceride-induced acute pancreatitis.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 24, 2020 | Convertable Note | $827.33K | 1 | — | — | Detail |
Apr 25, 2018 | Series B | $60M | 9 | Venrock | — | Detail |
Feb 17, 2016 | Series A | $26M | 2 | Apple Tree Partners Sofinnova Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Venrock | Yes | Series B |
HBM Healthcare Investments AG | — | Convertable Note |
Andera Partners | — | Series B |
Apple Tree Partners | — | Series B |
Cormorant Asset Management | — | Series B |
Fresenius Medical Care | — | Series B |
MedImmune | — | Series B |
Sofinnova Partners | — | Series B |
Venrock Healthcare Capital Partners | — | Series B |